Video Experimental Relacionado
Updated: Jan 14, 2026

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
Published on: June 27, 2025
Más allá de la carga: Elevación de la inmunoterapia en el cáncer colorrectal
Christine M Parseghian1, Madhulika Eluri2
1The University of Texas MD Anderson Cancer Center Houston, Texas United States.
Abstract:
Colorectal cancers treated with targeted therapies frequently acquire numerous subclonal genomic alterations. Tumor mutation burden (TMB) is under investigation as a biomarker for predicting response to immunotherapy in microsatellite-stable metastatic colorectal cancer. Here, we contextualize a recent study evaluating high plasma TMB post-targeted therapy and its implications for immunotherapy.
Más Videos Relacionados
Videos de Conceptos Relacionados
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Drugs for Treatment of Ulcerative Colitis in IBD
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...

